Green Tea: Booming in India, Restricted in Europe

Walk into any pharmacy or open any D2C wellness brand and you will find it. The label may say green tea extract, it may say EGCG, it may say Camellia sinensis. It is the same ingredient, and Indian companies have built serious supply chains around it: weight-management capsules, metabolism boosters, antioxidant blends, and increasingly supplements marketed alongside GLP-1 support claims.

This is not about green tea drinks. Not matcha. Not the tea bag in your morning cup.

When you brew a cup, you consume a dilute infusion. The compound that gives green tea its health reputation is EGCG, epigallocatechin-3-gallate, and it is the reason the supplement industry built a whole weight-management category around the leaf. In a normal cup you get somewhere between 90 and 150 mg of it. Three cups a day might reach 300 mg. European regulators looked at that level and called it generally safe.

Now consider what happens when the same leaf is processed differently. Extract concentrates the active compounds into a form that goes into capsules, tablets, and health drinks. A single capsule sold in India today can contain 200 to 300 mg of EGCG. Two or three a day, which many products recommend, can take a consumer past 600 mg, and in some formulations past 800.

That is not the same thing as drinking tea. The European Commission drew a hard scientific line: not a ban, but a restriction with conditions, and the conditions matter enormously.

At 800 mg of EGCG per day from concentrated extracts, European food-safety regulators found measurable liver-stress markers in clinical-trial participants. The Commission responded by restricting products at or above 800 mg per daily portion, placing all green tea extracts under ongoing scrutiny, and requiring mandatory warning labels for products sold in Europe.

Check whether your label carries any of them.

In India, FSSAI recognises nutraceuticals as a legal category. Green tea catechins including EGCG are listed as a permitted nutraceutical ingredient, and a brand can make health claims if they are scientifically substantiated and FSSAI-approved. The framework exists, it is evolving, and Indian brands have navigated it successfully.

In Europe, a health claim is not a marketing decision. It is a formal authorisation, evaluated by the European Food Safety Authority, approved by the Commission, and listed in a public register. If a claim is not on that list, it cannot appear on the label. The weight-management claim for green tea was reviewed, rejected, and removed.

India is one of the largest producers of green tea extract for global supply chains. If you sell to European food or supplement manufacturers, your buyers now operate under these restrictions. They need EGCG content clearly specified per batch, documentation that the ingredient meets European conditions, and answers to questions their Indian suppliers may not yet be prepared to give. The implication of a European restriction does not stop at the European brand. It travels back to the ingredient source.

If you are a nutraceutical startup, decide which markets you want to enter before you finalise formulation and label, because each market will ask different things of your product. If you are a supplement brand, check your EGCG content per daily dose and check what your label does and does not say; what is acceptable in India may not be acceptable in the EU. If you are an ingredient exporter, your European buyers already know this regulation, and being the supplier who can speak to it fluently is a commercial advantage.

The 2022 action is not a story about tea being dangerous. It is a story about how health claims, dosage science, and regulatory frameworks can look completely different depending on which market you are in, and how that difference has real consequences for your business.